Biggie Balls Enclomiphene 30 count 12.5 mg capsules



Background

Secondary hypogonadism (pituitary failure) is described by low serum testosterone with normal or low luteinizing hormone (LH) levels. ³ There are multiple causes of secondary hypogonadism that include HIV, Kallman syndrome, obesity, pituitary disorders, stress-induced hypogonadism, surgery, and trauma. ⁴ Various reports suggest that upwards of 40% of men older than 45 and half of men in their 80s are hypogonadal. ^{5, 6, 7} The onset of secondary hypogonadism develops when chemical signaling to the testes from either the hypothalamus, LH, or the pituitary by Gonadotropin-releasing hormone (GnRH) is unable to stimulate sufficient Leydig cell testosterone production, causing a known risk factor for cardiovascular disease. ^{3, 9, 10}

The pathophysiology of testosterone has three primary hormonal effects including targeted activity on specific androgen receptors, estrogenic effect when converted to estradiol by aromatase, and secondary actions by intracellular conversion to dihydrotestosterone by 5-alpha reductase, as in prostate cells. ⁸

Enclomiphene homeopathic formulary is a supplemental blend derivative capsule that is a pure isomer (the trans-isomer) of clomiphene citrate, a compound that is used to stimulate ovulation and treat infertility in women. ²⁶ As a pure isomer synthetic isolated from the mixture, Enclomiphene leads to more targeted effects and fewer estrogenic results. ²⁶ Enclomiphene is not categorized as a form of testosterone replacement therapy (TRT), as it promotes the body's own testosterone production instead of supplementing it with exogenous testosterone. ²

Research

Wiehle et al. (2013) investigates testosterone restoration using **Enclomiphene** in men with secondary hypogonadism performing a pharmacodynamic and pharmacokinetic study. ¹ In their randomized, single-blind, two-center, phase II study (n = 48) employing three different doses of Enclomiphene citrate (6.25, 12.5 and 25 mg) vs transdermal testosterone, the researchers discovered Enclomiphene citrate increased serum luteinizing hormone (LH) & total testosterone

1 | Biggie Balls paper

and Enclomiphene citrate steadily increased serum total testosterone into the normal range and increased LH and follicle stimulating hormone (FSH) above the normal range. ¹

Testosterone therapy has been employed in recognized hypogonadal men for many years and has been evidenced in clinical trials to generate statistically significant improvements in anemia, bone mineral density, depression, erectile dysfunction, lean body mass, and libido. ^{9, 11, 12, 13, 14, 15} Other less studied areas include improvements in cognitive function, diabetes control, energy levels, fatigue hyperlipidemia, and perceived quality of life metrics. ^{9, 16, 17, 18, 19}

Enclomiphene might be applicable treatment for both biochemical and clinical male hypogonadism by a distinctive mechanism of action. ^{20, 21, 22} As an anti-estrogen it works by making the body think that testosterone levels are lower than actual levels by stopping estradiol from lowering gonadotropin-releasing hormone (GnRH) production in the hypothalamus — thus, initiates the pituitary gland to release more FSH and LH. ²⁰ This cascade of events is important for overall male sexual health. The expanded FSH supports fertility and sperm counts, and the LH assists to boost testosterone levels. ^{20, 21, 23}

Conclusion

Enclomiphene is approved by the FDA and has been used in women to initiate ovulation. ¹ The selective estrogen receptor modulator (SERM) is gaining attention for ability to increase LH, FSH, and testosterone levels in men with fertility and secondary hypogonadism health issues. ¹ Different from selective androgen receptor modulators (SARMs) that selectively activate the androgen receptor in specific tissues, Enclomiphene binds with estrogen receptors in the hypothalamus of the brain and blocks estrogen production. ² After the SERM blocks estrogen release, it indicates the hypothalamus to boost total testosterone in males and harmonize hormone levels. ² It has been suggested to be most effective in raising testosterone in patients with secondary hypogonadism with verified lower LH levels. ^{20, 24} Researchers express fair confidence that Enclomiphene is a primary therapeutic recommendation for men wanting to maintain their sperm counts and enhance fertility. ^{20, 25}

References

- ¹ Wiehle R, Cunningham GR, Pitteloud N, Wike J, Hsu K, Fontenot GK, Rosner M, Dwyer A, Podolski J. Testosterone Restoration by EnEnclomiphene Citrate in Men with Secondary Hypogonadism: Pharmacodynamics and Pharmacokinetics. BJU Int. 2013 Jul 12;112(8):1188–200. doi: 10.1111/bju.12363. Epub ahead of print. PMID: 23875626; PMCID: PMC4155868.
- ² Marshall, Dr. F. J., & Nanotech Project. (2024, March 4). EnEnclomiphene Citrate: Benefits, Side Effects, and Dosage. https://nanotechproject.org/enEnclomiphene/.
- ³ Sizar O, Leslie SW, Schwartz J. Male Hypogonadism. [Updated 2024 Feb 25]. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2025 Jan-. Available from: https://www.ncbi.nlm.nih.gov/books/NBK532933/.
- ⁴ Dandona P, Rosenberg MT. A practical guide to male hypogonadism in the primary care setting. Int J Clin Pract. 2010 May;64(6):682-96. doi: 10.1111/j.1742-1241.2010.02355.x. PMID: 20518947; PMCID: PMC2948422.
- ⁵ Harman SM, Metter EJ, Tobin JD, Pearson J, Blackman MR; Baltimore Longitudinal Study of Aging. Longitudinal effects of aging on serum total and free testosterone levels in healthy men. Baltimore Longitudinal Study of Aging. J Clin Endocrinol Metab. 2001 Feb;86(2):724-31. doi: 10.1210/jcem.86.2.7219. PMID: 11158037.
- ⁶ Mulligan T, Frick MF, Zuraw QC, Stemhagen A, McWhirter C. Prevalence of hypogonadism in males aged at least 45 years: the HIM study. Int J Clin Pract. 2006 Jul;60(7):762-9. doi: 10.1111/j.1742-1241.2006.00992.x. PMID: 16846397; PMCID: PMC1569444.
- ⁷ Liu N, Feng Y, Ma X, Ma F. Prevalence of testosterone deficiency among US adult males. Aging Male. 2022 Dec;25(1):278-280. doi: 10.1080/13685538.2022.2130236. PMID: 36399329.
- ⁸ Sizar O, Leslie SW, Pico J. Androgen Replacement. 2023 Nov 25. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2025 Jan–. PMID: 30521274.
- ⁹ Mulhall JP, Trost LW, Brannigan RE, Kurtz EG, Redmon JB, Chiles KA, Lightner DJ, Miner MM, Murad MH, Nelson CJ, Platz EA, Ramanathan LV, Lewis RW. Evaluation and Management of Testosterone Deficiency: AUA Guideline. J Urol. 2018 Aug;200(2):423-432. doi: 10.1016/j.juro.2018.03.115. Epub 2018 Mar 28. PMID: 29601923.
- ¹⁰ Kloner RA, Carson C 3rd, Dobs A, Kopecky S, Mohler ER 3rd. Testosterone and Cardiovascular Disease. J Am Coll Cardiol. 2016 Feb 9;67(5):545-57. doi: 10.1016/j.jacc.2015.12.005. PMID: 26846952.

- ¹¹ Snyder PJ, Bhasin S, Cunningham GR, Matsumoto AM, Stephens-Shields AJ, Cauley JA, Gill TM, Barrett-Connor E, Swerdloff RS, Wang C, Ensrud KE, Lewis CE, Farrar JT, Cella D, Rosen RC, Pahor M, Crandall JP, Molitch ME, Cifelli D, Dougar D, Fluharty L, Resnick SM, Storer TW, Anton S, Basaria S, Diem SJ, Hou X, Mohler ER 3rd, Parsons JK, Wenger NK, Zeldow B, Landis JR, Ellenberg SS; Testosterone Trials Investigators. Effects of Testosterone Treatment in Older Men. N Engl J Med. 2016 Feb 18;374(7):611-24. doi: 10.1056/NEJMoa1506119. PMID: 26886521; PMCID: PMC5209754.
- ¹² Snyder PJ, Kopperdahl DL, Stephens-Shields AJ, Ellenberg SS, Cauley JA, Ensrud KE, Lewis CE, Barrett-Connor E, Schwartz AV, Lee DC, Bhasin S, Cunningham GR, Gill TM, Matsumoto AM, Swerdloff RS, Basaria S, Diem SJ, Wang C, Hou X, Cifelli D, Dougar D, Zeldow B, Bauer DC, Keaveny TM. Effect of Testosterone Treatment on Volumetric Bone Density and Strength in Older Men With Low Testosterone: A Controlled Clinical Trial. JAMA Intern Med. 2017 Apr 1;177(4):471-479. doi: 10.1001/jamainternmed.2016.9539. Erratum in: JAMA Intern Med. 2017 Apr 1;177(4):600. doi: 10.1001/jamainternmed.2017.0968. Erratum in: JAMA Intern Med. 2019 Mar 1;179(3):457. doi: 10.1001/jamainternmed.2019.0249. PMID: 28241231; PMCID: PMC5433755.
- ¹³ Amory JK, Watts NB, Easley KA, Sutton PR, Anawalt BD, Matsumoto AM, Bremner WJ, Tenover JL. Exogenous testosterone or testosterone with finasteride increases bone mineral density in older men with low serum testosterone. J Clin Endocrinol Metab. 2004 Feb;89(2):503-10. doi: 10.1210/jc.2003-031110. PMID: 14764753.
- ¹⁴ Wang YJ, Zhan JK, Huang W, Wang Y, Liu Y, Wang S, Tan P, Tang ZY, Liu YS. Effects of low-dose testosterone undecanoate treatment on bone mineral density and bone turnover markers in elderly male osteoporosis with low serum testosterone. Int J Endocrinol. 2013;2013:570413. doi: 10.1155/2013/570413. Epub 2013 Mar 4. PMID: 23533404; PMCID: PMC3603196.
- ¹⁵ Gianatti EJ, Dupuis P, Hoermann R, Strauss BJ, Wentworth JM, Zajac JD, Grossmann M. Effect of testosterone treatment on glucose metabolism in men with type 2 diabetes: a randomized controlled trial. Diabetes Care. 2014 Aug;37(8):2098-107. doi: 10.2337/dc13-2845. Epub 2014 May 7. PMID: 24804695.
- ¹⁶ Cherrier MM, Anderson K, Shofer J, Millard S, Matsumoto AM. Testosterone treatment of men with mild cognitive impairment and low testosterone levels. Am J Alzheimers Dis Other Demen. 2015 Jun;30(4):421-30. doi: 10.1177/1533317514556874. Epub 2014 Nov 11. PMID: 25392187; PMCID: PMC10852633.
- ¹⁷ Corona G, Giagulli VA, Maseroli E, Vignozzi L, Aversa A, Zitzmann M, Saad F, Mannucci E, Maggi M. Testosterone supplementation and body composition: results from a meta-analysis of observational studies. J Endocrinol Invest. 2016 Sep;39(9):967-81. doi: 10.1007/s40618-016-0480-2. Epub 2016 May 30. PMID: 27241317.

4 | Biggie Balls paper

- ¹⁸ Brock G, Heiselman D, Maggi M, Kim SW, Rodríguez Vallejo JM, Behre HM, McGettigan J, Dowsett SA, Hayes RP, Knorr J, Ni X, Kinchen K. Effect of Testosterone Solution 2% on Testosterone Concentration, Sex Drive and Energy in Hypogonadal Men: Results of a Placebo Controlled Study. J Urol. 2016 Mar;195(3):699-705. doi: 10.1016/j.juro.2015.10.083. Epub 2015 Oct 20. PMID: 26498057.
- ¹⁹ Ho CC, Tong SF, Low WY, Ng CJ, Khoo EM, Lee VK, Zainuddin ZM, Tan HM. A randomized, double-blind, placebo-controlled trial on the effect of long-acting testosterone treatment as assessed by the Aging Male Symptoms scale. BJU Int. 2012 Jul;110(2):260-5. doi: 10.1111/j.1464-410X.2011.10755.x. Epub 2011 Nov 17. PMID: 22093057.
- ²⁰ Da Ros CT, Da Ros LU, Da Ros JPU. The role of Enclomiphene citrate in late onset male hypogonadism. Int Braz J Urol. 2022 Sep-Oct;48(5):850-856. doi: 10.1590/S1677-5538.IBJU.2021.0724. PMID: 35168314; PMCID: PMC9388170.
- ²¹ Delu A, Kiltz RJ, Kuznetsov VA, Trussell JC. Enclomiphene citrate improved testosterone and sperm concentration in hypogonadal males. Syst Biol Reprod Med. 2020 Dec;66(6):364-369. doi: 10.1080/19396368.2020.1822457. Epub 2020 Oct 12. PMID: 33043679.
- ²² Guay AT, Jacobson J, Perez JB, Hodge MB, Velasquez E. Enclomiphene increases free testosterone levels in men with both secondary hypogonadism and erectile dysfunction: who does and does not benefit? Int J Impot Res. 2003 Jun;15(3):156-65. doi: 10.1038/sj.ijir.3900981. PMID: 12904801.
- ²³ Wheeler KM, Sharma D, Kavoussi PK, Smith RP, Costabile R. Enclomiphene Citrate for the Treatment of Hypogonadism. Sex Med Rev. 2019 Apr;7(2):272-276. doi: 10.1016/j.sxmr.2018.10.001. Epub 2018 Dec 3. PMID: 30522888.
- ²⁴ Ide V, Vanderschueren D, Antonio L. Treatment of Men with Central Hypogonadism: Alternatives for Testosterone Replacement Therapy. Int J Mol Sci. 2020 Dec 22;22(1):21. doi: 10.3390/ijms22010021. PMID: 33375030; PMCID: PMC7792781.
- ²⁵ Huijben M, Lock MTWT, de Kemp VF, de Kort LMO, van Breda HMK. Enclomiphene citrate for men with hypogonadism: a systematic review and meta-analysis. Andrology. 2022 Mar;10(3):451-469. doi: 10.1111/andr.13146. Epub 2022 Jan 8. PMID: 34933414.
- ²⁶ Van Maele, Dr. R. (2024, September 4). What's the Difference Between Clomiphene and Enclomiphene? Rex MD. https://rexmd.com/learn/difference-between-clomiphene-andenclomiphene.

All: (a) content or statements appearing in this information paper have not been evaluated by the Food and Drug Administration, (b) product or related claims and provisions are not intended to diagnose, treat, cure, or prevent any disease, (c) content or statements appearing in this document are not intended to substitute for professional medical advice. For educational purposes only.

5 | Biggie Balls paper

Summary

Enclomiphene homeopathic formulary is a supplemental blend derivative capsule that is a pure isomer (the trans-isomer) of clomiphene citrate, a compound that is used to stimulate ovulation and treat infertility in women and secondary hypogonadism (pituitary failure) in men. Secondary hypogonadism is described by low serum testosterone with normal or low luteinizing hormone (LH) levels. The onset of secondary hypogonadism develops when chemical signaling to the testes from either the hypothalamus, LH, or the pituitary by Gonadotropin-releasing hormone (GnRH) is unable to stimulate sufficient Leydig cell testosterone production, causing a known risk factor for cardiovascular disease. Testosterone therapy has been employed in recognized hypogonadal men for many years and has been evidenced in clinical trials to generate statistically significant improvements in anemia, bone mineral density, depression, erectile dysfunction, lean body mass, and libido. Enclomiphene is not categorized as a form of testosterone replacement therapy (TRT), as it promotes the body's own testosterone production instead of supplementing it with exogenous testosterone. As an anti-estrogen it works by making the body think that testosterone levels are lower than actual levels by stopping estradiol from lowering gonadotropin-releasing hormone (GnRH) production in the hypothalamus - thus, initiates the pituitary gland to release more follicle stimulating hormone (FSH) and luteinizing hormone (LH). This mechanism of action produces an organic boost in total testosterone and overall male sexual health.